BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 27799281)

  • 21. Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma.
    Sahm F; Reuss D; Koelsche C; Capper D; Schittenhelm J; Heim S; Jones DT; Pfister SM; Herold-Mende C; Wick W; Mueller W; Hartmann C; Paulus W; von Deimling A
    Acta Neuropathol; 2014 Oct; 128(4):551-9. PubMed ID: 25143301
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma.
    Ceccarelli M; Barthel FP; Malta TM; Sabedot TS; Salama SR; Murray BA; Morozova O; Newton Y; Radenbaugh A; Pagnotta SM; Anjum S; Wang J; Manyam G; Zoppoli P; Ling S; Rao AA; Grifford M; Cherniack AD; Zhang H; Poisson L; Carlotti CG; Tirapelli DP; Rao A; Mikkelsen T; Lau CC; Yung WK; Rabadan R; Huse J; Brat DJ; Lehman NL; Barnholtz-Sloan JS; Zheng S; Hess K; Rao G; Meyerson M; Beroukhim R; Cooper L; Akbani R; Wrensch M; Haussler D; Aldape KD; Laird PW; Gutmann DH; ; Noushmehr H; Iavarone A; Verhaak RG
    Cell; 2016 Jan; 164(3):550-63. PubMed ID: 26824661
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reliability of IDH1-R132H and ATRX and/or p53 immunohistochemistry for molecular subclassification of Grade 2/3 gliomas.
    Nishikawa T; Watanabe R; Kitano Y; Yamamichi A; Motomura K; Ohka F; Aoki K; Hirano M; Kato A; Yamaguchi J; Maeda S; Kibe Y; Saito R; Wakabayashi T; Kato Y; Sato S; Ogino T; Natsume A; Ito I
    Brain Tumor Pathol; 2022 Jan; 39(1):14-24. PubMed ID: 34826036
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular and histologic characteristics of pseudoprogression in diffuse gliomas.
    Lin AL; White M; Miller-Thomas MM; Fulton RS; Tsien CI; Rich KM; Schmidt RE; Tran DD; Dahiya S
    J Neurooncol; 2016 Dec; 130(3):529-533. PubMed ID: 27704386
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic implications of TERT promoter mutation status in diffuse gliomas in a routine clinical setting.
    Hewer E; Prebil N; Berezowska S; Gutt-Will M; Schucht P; Dettmer MS; Vassella E
    Virchows Arch; 2017 Nov; 471(5):641-649. PubMed ID: 28823044
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma.
    Kannan K; Inagaki A; Silber J; Gorovets D; Zhang J; Kastenhuber ER; Heguy A; Petrini JH; Chan TA; Huse JT
    Oncotarget; 2012 Oct; 3(10):1194-203. PubMed ID: 23104868
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical impact of revisions to the WHO classification of diffuse gliomas and associated future problems.
    Sonoda Y
    Int J Clin Oncol; 2020 Jun; 25(6):1004-1009. PubMed ID: 32020379
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular Classification of Diffuse Gliomas.
    Kalidindi N; Or R; Babak S; Mason W
    Can J Neurol Sci; 2020 Jul; 47(4):464-473. PubMed ID: 31918786
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radiation-induced gliomas: a report of four cases and analysis of molecular biomarkers.
    Nakao T; Sasagawa Y; Nobusawa S; Takabatake Y; Sabit H; Kinoshita M; Miyashita K; Hayashi Y; Yokoo H; Nakada M
    Brain Tumor Pathol; 2017 Oct; 34(4):149-154. PubMed ID: 28795231
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ATRX status correlates with 11 C-methionine uptake in WHO grade II and III gliomas with IDH1 mutations.
    Ogishima T; Tamura K; Kobayashi D; Inaji M; Hayashi S; Tamura R; Nariai T; Ishii K; Maehara T
    Brain Tumor Pathol; 2017 Jan; 34(1):20-27. PubMed ID: 28251430
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Subgroup characteristics of insular low-grade glioma based on clinical and molecular analysis of 42 cases.
    Tang C; Zhang ZY; Chen LC; Sun Z; Zhang Y; Qin Z; Yao Y; Zhou LF
    J Neurooncol; 2016 Feb; 126(3):499-507. PubMed ID: 26586262
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biphasic IDH1 phenotype in a diffusely infiltrating glioma: implications for pathogenesis, treatment and prognosis.
    Odia Y; Varma H; Tsankova NM
    Clin Neuropathol; 2015; 34(5):282-7. PubMed ID: 25907263
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Application of ATRX in diagnosis and prognostic evaluation of glioma].
    Li Z; Piao YS; Zhang LY; Wang LM; Wang DD; Fu YJ; Cai YN; Lu DH
    Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):690-694. PubMed ID: 29050070
    [No Abstract]   [Full Text] [Related]  

  • 34. [Update on the 2016 WHO classification of tumors of the central nervous system - Part 1: Diffusely infiltrating gliomas].
    Švajdler M; Rychlý B; Zámečník J; Švajdler P
    Cesk Patol; 2017; 53(1):12-21. PubMed ID: 28248117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
    Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
    Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.
    Dubbink HJ; Atmodimedjo PN; Kros JM; French PJ; Sanson M; Idbaih A; Wesseling P; Enting R; Spliet W; Tijssen C; Dinjens WN; Gorlia T; van den Bent MJ
    Neuro Oncol; 2016 Mar; 18(3):388-400. PubMed ID: 26354927
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas.
    Cryan JB; Haidar S; Ramkissoon LA; Bi WL; Knoff DS; Schultz N; Abedalthagafi M; Brown L; Wen PY; Reardon DA; Dunn IF; Folkerth RD; Santagata S; Lindeman NI; Ligon AH; Beroukhim R; Hornick JL; Alexander BM; Ligon KL; Ramkissoon SH
    Oncotarget; 2014 Sep; 5(18):8083-92. PubMed ID: 25257301
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and FUBP1.
    Cahill DP; Louis DN; Cairncross JG
    CNS Oncol; 2015; 4(5):287-94. PubMed ID: 26545048
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dual-Genotype Diffuse Low-Grade Glioma: Is It Really Time to Abandon Oligoastrocytoma As a Distinct Entity?
    Barresi V; Lionti S; Valori L; Gallina G; Caffo M; Rossi S
    J Neuropathol Exp Neurol; 2017 May; 76(5):342-346. PubMed ID: 28419269
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic significance of histomolecular subgroups of adult anaplastic (WHO Grade III) gliomas: applying the 'integrated' diagnosis approach.
    Rajmohan KS; Sugur HS; Shwetha SD; Ramesh A; Thennarasu K; Pandey P; Arivazhagan A; Santosh V
    J Clin Pathol; 2016 Aug; 69(8):686-94. PubMed ID: 26743027
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.